[go: up one dir, main page]

AR020070A1 - UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE. - Google Patents

UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.

Info

Publication number
AR020070A1
AR020070A1 ARP990101987A ARP990101987A AR020070A1 AR 020070 A1 AR020070 A1 AR 020070A1 AR P990101987 A ARP990101987 A AR P990101987A AR P990101987 A ARP990101987 A AR P990101987A AR 020070 A1 AR020070 A1 AR 020070A1
Authority
AR
Argentina
Prior art keywords
beta
polyol
production
pharmaceutical composition
understands
Prior art date
Application number
ARP990101987A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR020070A1 publication Critical patent/AR020070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se producen conjungados poliol-interferon (IFN) beta, en los cuales hay una porcion poliol covalentemente unida a la Cys17 del IFN beta humano, por unproceso de PEGilacion de sitio específico con un agente de PEGilacion reactivo con tiol. Procesopar a su produccion, una composicion farmacéutica y el uso delos mismos para la manufactura de un medicamento para tratar infecciones, tumores y enfermedades autoinmunes e inflamatorias. Método para la adhesion poretapas de porciones PEG en serie aun po lipéptido, y más específicamente al IFN beta.
ARP990101987A 1998-04-28 1999-04-29 UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE. AR020070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
AR020070A1 true AR020070A1 (es) 2002-04-10

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101987A AR020070A1 (es) 1998-04-28 1999-04-29 UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.

Country Status (30)

Country Link
US (3) US6638500B1 (es)
EP (2) EP1421956B1 (es)
JP (2) JP4574007B2 (es)
KR (1) KR100622796B1 (es)
CN (2) CN100335503C (es)
AR (1) AR020070A1 (es)
AT (2) ATE275422T1 (es)
AU (1) AU762621B2 (es)
BG (2) BG64694B1 (es)
BR (1) BR9910023A (es)
CA (2) CA2565375A1 (es)
CY (1) CY1108022T1 (es)
CZ (2) CZ298597B6 (es)
DE (2) DE69920002T2 (es)
DK (2) DK1075281T3 (es)
EA (2) EA003789B1 (es)
EE (1) EE05214B1 (es)
ES (2) ES2224649T3 (es)
HU (1) HUP0300548A3 (es)
IL (1) IL139286A (es)
NO (2) NO329749B1 (es)
NZ (1) NZ507456A (es)
PL (2) PL196533B1 (es)
PT (2) PT1421956E (es)
SI (2) SI1421956T1 (es)
SK (2) SK286217B6 (es)
TR (2) TR200003161T2 (es)
TW (2) TWI266800B (es)
UA (2) UA66857C2 (es)
WO (1) WO1999055377A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
EA004789B9 (ru) * 1998-10-16 2017-05-31 Байоджен, Инк. Полимерные конъюгаты бета-1а-интерферона и их использование
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
CA2369595C (en) * 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (es) * 1999-10-15 2001-08-21
ATE522563T1 (de) * 1999-12-24 2011-09-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
CA2397347C (en) 2000-02-11 2011-07-12 Maxygen Aps Factor vii or viia-like molecules
DE60236796D1 (de) 2001-01-30 2010-08-05 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
BRPI0306993B8 (pt) 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
EP1608745B1 (en) 2003-03-20 2009-05-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
NZ548255A (en) * 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
AU2005244448B2 (en) 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7851565B2 (en) † 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP2009503111A (ja) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
JP4944112B2 (ja) 2005-08-26 2012-05-30 アレス トレーディング ソシエテ アノニム グリコシル化されたインターフェロンベータの調製方法
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US7632492B2 (en) * 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
AU2007253264A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
JP2010525821A (ja) * 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
HRP20120483T1 (hr) * 2007-12-20 2012-07-31 Merck@Serono@SA Formulacije peg interferona beta
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
EP2593130A2 (en) 2010-07-15 2013-05-22 Novo Nordisk A/S Stabilized factor viii variants
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
EP2676675B1 (en) 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2762489B1 (en) * 2011-10-01 2018-03-28 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
PE20142451A1 (es) 2012-02-27 2015-02-04 Amunix Operating Inc Composiciones de conjugados de xten y metodos para realizar las mismas
MX2014010209A (es) 2012-02-29 2014-11-21 Toray Industries Agente inhibidor para acumulacion de fluido de la cavidad corporal.
CN104334574B (zh) 2013-03-29 2020-01-14 株式会社糖锁工学研究所 附加唾液酸化糖链的多肽
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2017030563A1 (en) 2014-08-19 2017-02-23 Biogen Ma Inc Pegylation method
WO2016179007A1 (en) 2015-05-01 2016-11-10 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
CA2989637C (en) * 2015-06-19 2023-01-10 Eisai R&D Management Co., Ltd. Cys80 conjugated immunoglobulins
NZ741552A (en) 2015-11-09 2022-04-29 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
EP3612214A4 (en) * 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
JP7495345B2 (ja) 2017-11-24 2024-06-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
CA3125320A1 (en) 2019-01-28 2020-08-06 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
BR112021012472A2 (pt) 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
NZ285664A (en) * 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
US20070141620A1 (en) 2007-06-21
NO20005337D0 (no) 2000-10-23
CN100335503C (zh) 2007-09-05
BR9910023A (pt) 2000-12-26
NO332224B1 (no) 2012-07-30
HK1038194A1 (en) 2002-03-08
NO20100324L (no) 2000-12-28
WO1999055377A9 (en) 2000-03-02
EE200000614A (et) 2002-04-15
EA003789B1 (ru) 2003-10-30
SK286654B6 (sk) 2009-03-05
DK1075281T3 (da) 2005-01-03
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
IL139286A (en) 2005-12-18
DK1421956T3 (da) 2007-10-01
ATE275422T1 (de) 2004-09-15
EA005495B1 (ru) 2005-02-24
UA79430C2 (en) 2007-06-25
PT1075281E (pt) 2004-11-30
CA2565375A1 (en) 1999-11-04
CZ298597B6 (cs) 2007-11-21
DE69936409T2 (de) 2008-04-17
CN1637020A (zh) 2005-07-13
TWI266800B (en) 2006-11-21
BG64694B1 (bg) 2005-12-30
TR200101751T2 (tr) 2002-05-21
TWI232882B (en) 2005-05-21
EP1075281A2 (en) 2001-02-14
CZ298579B6 (cs) 2007-11-14
NO20005337L (no) 2000-12-28
AU762621B2 (en) 2003-07-03
EP1421956B1 (en) 2007-06-27
DE69920002T2 (de) 2005-09-22
JP2002512983A (ja) 2002-05-08
UA66857C2 (uk) 2004-06-15
NZ507456A (en) 2003-10-31
EP1421956A1 (en) 2004-05-26
IL139286A0 (en) 2001-11-25
BG104871A (en) 2001-07-31
SI1421956T1 (sl) 2007-10-31
HK1076115A1 (en) 2006-01-06
SK286217B6 (sk) 2008-05-06
PT1421956E (pt) 2007-07-13
NO329749B1 (no) 2010-12-13
US7700314B2 (en) 2010-04-20
ATE365563T1 (de) 2007-07-15
JP2010184929A (ja) 2010-08-26
BG109291A (en) 2006-04-28
CN1302209A (zh) 2001-07-04
PL196533B1 (pl) 2008-01-31
HUP0300548A2 (hu) 2003-06-28
HUP0300548A3 (en) 2005-07-28
PL344490A1 (en) 2001-11-05
ES2285286T3 (es) 2007-11-16
WO1999055377A3 (en) 1999-12-29
CN1187094C (zh) 2005-02-02
DE69936409D1 (de) 2007-08-09
PL193352B1 (pl) 2007-02-28
US6638500B1 (en) 2003-10-28
EA200001111A1 (ru) 2001-04-23
BG65046B1 (bg) 2007-01-31
SK16222000A3 (sk) 2001-04-09
AU3767499A (en) 1999-11-16
US7357925B2 (en) 2008-04-15
DE69920002D1 (de) 2004-10-14
KR100622796B1 (ko) 2006-09-13
US20040043002A1 (en) 2004-03-04
JP4574007B2 (ja) 2010-11-04
SI1075281T1 (en) 2005-02-28
CY1108022T1 (el) 2013-09-04
TR200003161T2 (tr) 2001-01-22
ES2224649T3 (es) 2005-03-01
WO1999055377A2 (en) 1999-11-04
KR20010071158A (ko) 2001-07-28
EA200300382A1 (ru) 2005-02-24
CA2330451A1 (en) 1999-11-04
CZ20003995A3 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
AR020070A1 (es) UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.
BRPI0112962B8 (pt) composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
SI1667522T1 (en) Modified oligonucleotides for the inhibition of telomerase
DK1066044T3 (da) Dextranformuleringer til behandling af inflammatoriske ledsygdomme
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
EP0859603A4 (en) PROLONGED RELEASE MATRIX FOR HIGH DOSAGE INSOLUBLE DRUGS
BRPI0410260A (pt) composição conjugada para medicamento
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
ATE232396T1 (de) Oxydiertes thymosin beta 4
ES2099075T3 (es) Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.
IT1235358B (it) Derivati 17beta-oh 19-nor steroidei sostituiti in 17alfa, procedimento di preparazione, loro impiego come medicamenti e composizioni farmaceutiche che li compongono
AR026801A1 (es) Sustancias para uso en el tratamiento de la psoriasis
BR0109294A (pt) •ster polissacarìdico, composições farmacêuticas, uso do éster polissacarìdico, e, processo para a preparação dos ésteres polissacarìdicos
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
AR020832A1 (es) Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona

Legal Events

Date Code Title Description
FG Grant, registration